Alimta for Mesothelioma to Be Available on Expanded Access Basis

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 9
Volume 11
Issue 9

INDIANAPOLIS-Based on phase III trial results presented at ASCO (see ONI, July 2002, page 1), Eli Lilly and Company and the US Food and Drug Administration have reached an agreement to make Alimta (pemetrexed) available on an expanded access, or compassionate use, basis to medically eligible patients with malignant pleural mesothelioma. Lilly is pursuing approval of Alimta in combination with cisplatin (Platinol) for this indication. For more information, physicians may call 1-866-347-9503.

INDIANAPOLIS—Based on phase III trial results presented at ASCO (see ONI, July 2002, page 1), Eli Lilly and Company and the US Food and Drug Administration have reached an agreement to make Alimta (pemetrexed) available on an expanded access, or compassionate use, basis to medically eligible patients with malignant pleural mesothelioma. Lilly is pursuing approval of Alimta in combination with cisplatin (Platinol) for this indication. For more information, physicians may call 1-866-347-9503.

Related Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
A panel of 4 experts on multiple myeloma
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Video 1 - 4 KOLs are featured in "Triaging and Prioritizing Patients with Multiple Myeloma"
Video 1 - 4 KOLs are featured in "CAR T-Cell Therapy: Leukapheresis Practices"
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content